Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9947667 | 0.74 | VCAM1 (0.39) | VCAM1ACP1MEN1GALR3HTT | |
| SCHEMBL1530129 | 0.71 | HTT (0.47) | ACP1MEN1GALR3HTTKMT2A | |
| SCHEMBL13031098 | 0.69 | HTT (0.41) | ACP1MEN1GALR3HTTKMT2A | |
| SCHEMBL360973 | 0.67 | HTT (0.40) | ACP1MEN1GALR3HTTKMT2A | |
| SCHEMBL360974 | 0.67 | HTT (0.40) | ACP1MEN1GALR3HTTKMT2A | |
| SCHEMBL788056 | 0.65 | ALDH1A1 (0.47) | ACP1 | |
| SCHEMBL29698750 | 0.65 | ALDH1A1 (0.47) | ACP1 | |
| SCHEMBL16713699 | 0.65 | BACE1 (0.31) | — | |
| Nitrogen SCHEMBL27917117 | 0.64 | CYP19A1 (0.56) | VCAM1ACP1MEN1HTTKMT2A | |
| SCHEMBL219410 | 0.63 | CYP19A1 (0.55) | VCAM1ACP1MEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021520-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021520-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | VCAM1 3670/4885ACP1 4841/4885MEN1 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.